- Home
- CRIS vs MDCX Comparison
CRIS vs MDCX Comparison
Compare CRIS & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- MDCX
- Stock Information
- Founded
- CRIS 2000
- MDCX 2008
- Country
- CRIS United States
- MDCX United States
- Employees
- CRIS N/A
- MDCX N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- MDCX
- Sector
- CRIS Health Care
- MDCX
- Exchange
- CRIS Nasdaq
- MDCX Nasdaq
- Market Cap
- CRIS 22.9M
- MDCX 36.2M
- IPO Year
- CRIS 2000
- MDCX N/A
- Fundamental
- Price
- CRIS $1.71
- MDCX $2.61
- Analyst Decision
- CRIS Strong Buy
- MDCX Strong Buy
- Analyst Count
- CRIS 2
- MDCX 2
- Target Price
- CRIS $16.50
- MDCX $23.50
- AVG Volume (30 Days)
- CRIS 74.8K
- MDCX 389.9K
- Earning Date
- CRIS 11-13-2025
- MDCX 08-11-2025
- Dividend Yield
- CRIS N/A
- MDCX N/A
- EPS Growth
- CRIS N/A
- MDCX N/A
- EPS
- CRIS N/A
- MDCX N/A
- Revenue
- CRIS $11,405,000.00
- MDCX N/A
- Revenue This Year
- CRIS $1.41
- MDCX N/A
- Revenue Next Year
- CRIS $7.46
- MDCX N/A
- P/E Ratio
- CRIS N/A
- MDCX N/A
- Revenue Growth
- CRIS 12.24
- MDCX N/A
- 52 Week Low
- CRIS $1.02
- MDCX $1.79
- 52 Week High
- CRIS $6.44
- MDCX $8.94
- Technical
- Relative Strength Index (RSI)
- CRIS 48.53
- MDCX 62.00
- Support Level
- CRIS $1.63
- MDCX $2.00
- Resistance Level
- CRIS $1.95
- MDCX $2.11
- Average True Range (ATR)
- CRIS 0.15
- MDCX 0.18
- MACD
- CRIS 0.01
- MDCX 0.09
- Stochastic Oscillator
- CRIS 29.41
- MDCX 91.11
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.